Topic Archives: Editas (EDIT)

Examining McCall’s “The First Trillion Dollar Patent Will Release the Largest Royalty Payments Ever Known to Mankind” pitch

Here’s a bit from the email that Matt McCall sent out introducing his lastest teaser ad: “When it comes down to it, there are really just three ways to get truly rich in the stock market. You can put thousands into the market every year, hold for decades, and retire with a fortune. You can […]

Looking into Jeff Brown’s “The ‘God Key’: The Most Revolutionary Biotechnology Since Antibiotics…”

The article below was originally published on November 27, 2017, when Jeff Brown’s ads promoting the “God Key” started to show up in our inboxes. It has not been updated or revised, but the new versions of the ad from Brown are very similar to the ones we covered in November, including the description of […]

Lichtenfeld’s “Genesis Cure” — “This single technology could wipe 4,800 incurable diseases off the face of the Earth”

Fear Of Missing Out is such a big deal that it gets its own acronym in my book (FOMO — and a clever FOMO-fueling website here), and it drives investors to take huge chances just so they don’t have to worry about missing a chance at stupendous gains. That’s what many newsletter ads use to […]

Comments

  • Avatar

    EDIT: Meant to post my question about $TDOC on the most recent article, moved it over to there just now....

  • Avatar

    Well I just hope this is a boomer like the "God Key" stocks (EDIT, CRSP) which are about 50% lower from their peaks in 2...

  • Avatar

    Although the last three months is a short time period, it's the only one I could research easily. Over that period, the...

  • Avatar

    That's how they make their money--from selling annual subscriptions with all kind of promises of riches and Porsches. Th...

  • Avatar

    "Crooks" is too strong a word, but I wasn't allowed to edit after submitting. I have no direct evidence of that. The mai...

  • Avatar

    ARK Genomic Revolution Multi-Sector ETF—ARKG This one has EDIT, CELG, NTLA, CRSP......

  • Avatar

    I think its cell data. https://www.investors.com/news/technology/crispr-gene-editing-biotech-companies/ https://mo...

  • Avatar

    There've been a lot of uncertainties around the CRISPR companies, but I think right now the elephant in the room is the ...

  • Avatar

    I bought EDIT Stock about 6 month ago and so far no gain but I still own it....

  • Avatar

    EDIT and CELG are Motley Fool favorites also. Lost money on CELG....

  • Avatar

    and back down with no sell , EDIT is being pumped again , join [sarcasm ]...

  • Avatar

    Found the article I remember that talks about the patent license. https://www.forbes.com/sites/matthewherper/2015/08/10/...

  • Avatar

    Don’t really understand the headline but I think Bill Gates put a bunch of money in Editas, which I’ve been in and o...

  • Avatar

    ""I found your allowance of thread authors to have an impact on editing content to be a very good solution, which should...

  • Avatar

    Thanks for putting everything into perspective. I read about "exciting new developments" every day, and it is impossibl...

  • Avatar

    Didn't EDIT win the big patent fight? It's too early as far as I'm concerned. I don't have enough time on the planet t...

  • Avatar

    I gave up on EDIT, NTLA, and CRSP and went with Illumina, Inc. (ILMN) which is similar but much less volatile. And ILMN ...

  • Travis Johnson, Stock Gumshoe

    Yes, EDIT, he's been pitching it similarly for over a year now -- my coverage is a bit old at this point, but if you wan...

  • Avatar

    My son did some research while I was at the hospital taking tests. The stock is EDIT, and it's at $32. I only had enou...

  • Avatar

    If you read all the way down to the end of Altucher's epic screed you see that he says you should buy all three: EDIT, N...

  • Travis Johnson, Stock Gumshoe

    That one has been around for a while, we covered it here: https://www.stockgumshoe.com/reviews/radical-technology-profit...

  • Avatar

    Incredibly interesting stuff. Thanks for shedding light. Many agree that the technology will have huge impact on medic...

  • Travis Johnson, Stock Gumshoe

    I have a really hard time with R&D companies or very early-stage clinical biotechs -- partly because it's an end market ...

  • Avatar

    Ha!! Caught again - thank you for being the best detective on Market Street....

  • Gr8Full!

    $GILD (KITE); $EDIT related - Jakobovits abruptly exits Adicet; Stanford researchers uncover mechanistic details of ALS ...

  • Travis Johnson, Stock Gumshoe

    This push is running hot and heavy again... with the urgency of the ad's claim that "a tiny $6 million startup is set to...

  • Avatar

    Editas (EDIT). Travis did a great review as this was recently re-pitched AGAIN as of Feb 2018. Not sorry missed out in ...

  • Avatar

    Yes, its Editas (EDIT). But the patent dispute was resolved a year ago. Not new news. They do have a good proprietary...

  • Avatar

    Outside of Stock Gumshoe, Technology and Opportunity (TAO) is the only other newsletter that i subscribe to. CALYXT (C...

  • Travis Johnson, Stock Gumshoe

    Yep, we covered that one here: https://www.stockgumshoe.com/reviews/radical-technology-profits/whats-the-6-million-start...

  • SoGiAm

    Comment Link: https://www.stockgumshoe.com/reviews/stansberry-venture/identifying-lashmets-december-31-2017-medical-brea...

  • Avatar

    my gut tells me it could be a one of these but Travis or others could help pin point. Editas, (edit) Cymabay (cbay) Inte...

  • Avatar

    so my gut tells me it could be a one of these but Travis or others could help pin point. Editas, (edit) Cymabay (cbay) I...

  • JohnM

    Prior post awaiting moderation, but this is timely Starting now Slingshot Insights Expert Interview @ 1PM EST - Join...

  • JohnM

    Starting in a few minutes Slingshot Insights Expert Interview @ 1PM EST - Join us for an in-depth conversation on CRI...

  • This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.

    Connect with Travis

    website designed by Gravity Switch